John Radford

21PUBLICATIONS
126CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursPredictive and prognostic markersAutoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Feb 05, 2026
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter transformation.

Katharine Louise Lewis, Sarit E Assouline, Ross Ian Baker

|Aug 14, 2025
Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study.

Alex F Herrera, Stephen M Ansell, Pier Luigi Zinzani

|Jan 08, 2025
Maximum tumor diameter is associated with relapse risk in limited-stage Hodgkin lymphoma: an international study.

Elizabeth H Phillips, Nicholas Counsell, Tim Illidge

|Oct 26, 2023
Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial.

Stefano Luminari, Alexander Fossa, Judith Trotman

|Oct 19, 2023
PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial.

Juan Pablo Alderuccio, Isildinha M Reis, Mehdi Hamadani

Pageof 4